Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Equity Average (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Equity Average for 7 consecutive years, with -$2.0 billion as the latest value for Q4 2025.

  • Quarterly Equity Average fell 50.17% to -$2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 billion through Dec 2025, down 50.17% year-over-year, with the annual reading at -$1.8 billion for FY2025, 26.55% down from the prior year.
  • Equity Average hit -$2.0 billion in Q4 2025 for BridgeBio Pharma, down from -$1.9 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$141.6 million in Q1 2021 to a low of -$2.0 billion in Q4 2025.
  • Historically, Equity Average has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2022.
  • Biggest five-year swings in Equity Average: crashed 598.6% in 2021 and later increased 17.33% in 2024.
  • Year by year, Equity Average stood at -$802.9 million in 2021, then tumbled by 47.67% to -$1.2 billion in 2022, then decreased by 7.04% to -$1.3 billion in 2023, then dropped by 5.46% to -$1.3 billion in 2024, then plummeted by 50.17% to -$2.0 billion in 2025.
  • Business Quant data shows Equity Average for BBIO at -$2.0 billion in Q4 2025, -$1.9 billion in Q3 2025, and -$1.7 billion in Q2 2025.